Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pumosetrag. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 2/20 | 0.98 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.48 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.48 |
| ▸ | HTR3D known ✓ | Q70Z44 | 1/20 | 0.48 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pumosetrag SCHEMBL1497905 | 1.00 | HTR3A (0.98) | HTR3ACYP3A4CHRNA7HTR3EHTR3B | |
| Pumosetrag SCHEMBL1497908 | 1.00 | HTR3A (0.98) | HTR3ACYP3A4CHRNA7HTR3EHTR3B | |
| Pumosetrag SCHEMBL390615 | 0.99 | HTR3A (1.00) | HTR3ACYP3A4CHRNA7HTR3EHTR3B | |
| Pumosetrag SCHEMBL1299656 | 0.99 | HTR3A (1.00) | HTR3ACYP3A4CHRNA7HTR3EHTR3B | |
| Pumosetrag SCHEMBL1299660 | 0.99 | HTR3A (1.00) | HTR3ACYP3A4CHRNA7HTR3EHTR3B | |
| Pumosetrag SCHEMBL1299759 | 0.97 | HTR3A (0.96) | HTR3ACYP3A4CHRNA7HTR3EHTR3B | |
| SCHEMBL1497938 | 0.95 | HTR3A (0.92) | HTR3ACYP3A4CHRNA7HTR3EHTR3B | |
| SCHEMBL1497911 | 0.91 | HTR3A (0.86) | HTR3ACYP3A4CHRNA7HTR3EHTR3B | |
| SCHEMBL1497977 | 0.83 | HTR3A (0.72) | HTR3ACYP3A4CHRNA7HTR3EHTR3B | |
| SCHEMBL1497721 | 0.77 | HTR3A (0.63) | HTR3ACYP3A4CHRNA7HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| US-20240002440-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | JPMORGAN CHASE BANK, N.A. | 2024-01-04 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230201143-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FIRST WAVE BIO, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11564896-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| EP-4045480-A1 | PHARMACEUTICAL FORMULATIONS | First Wave Bio, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| US-20220105057-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-04-07 | — | — | US | disclosed |
| US-20220079897-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | HTR3A 2259/4885HTR3E 1328/4885HTR3B 1701/4885 |
| US-20220079897-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | HTR3A 1100/4885HTR3E 1243/4885HTR3B 1651/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | HTR3A 1100/4885HTR3E 1243/4885HTR3B 1651/4885 |
| US-20230201143-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | HTR3A 1876/4885HTR3E 1824/4885HTR3B 2079/4885 |
| US-11564896-B2 | Methods of treatment | ACE2, ACE, SI | HTR3A 1876/4885HTR3E 1824/4885HTR3B 2079/4885 |
| US-20220105057-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | HTR3A 1876/4885HTR3E 1824/4885HTR3B 2079/4885 |
| US-20230102999-A1 | DEUTERATED NICLOSAMIDE | FH, IDH2, ECHS1 | HTR3A 2070/4885HTR3E 1296/4885HTR3B 1479/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | HTR3A 2268/4885HTR3E 1317/4885HTR3B 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.